You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 13, 2025

Patent: 10,272,142


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,272,142
Title:Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders
Abstract: Compositions and methods useful for the treatment of neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD) are disclosed.
Inventor(s): Broom; Colin (Devon, PA), Dayno; Jeffrey (Maple Glen, PA)
Assignee: SHIRE VIROPHARMA INCORPORATED (Lexington, MA)
Application Number:14/539,405
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Analyzing the Claims and Patent Landscape of United States Patent 10,272,142

Introduction

Patent 10,272,142, like any other patent, is a complex document that requires a thorough analysis to understand its implications and position within the broader patent landscape. This analysis will delve into the key aspects of the patent, including the claims, the legal framework governing patents, and the current trends and challenges in patent law.

Understanding Patent Claims

Patent claims are the heart of any patent application, as they define the scope of the invention and the rights granted to the patent holder. According to the USPTO, claims must "particularly point out and distinctly define the metes and bounds of the subject matter that will be protected by the patent grant"[4].

The Importance of Claim Clarity and Specificity

For a patent to be considered of high quality, its claims must meet the statutory requirements for novelty, clarity, and non-obviousness. The USPTO's Enhanced Patent Quality Initiative emphasizes the need for consistent definitions and measures of patent quality, including the clarity and specificity of claims[1].

Legal Framework: 35 U.S.C. § 101 and § 112

The patentability of an invention is governed by several sections of the U.S. Code, notably 35 U.S.C. § 101, which deals with subject matter eligibility, and 35 U.S.C. § 112, which requires that the specification conclude with one or more claims that particularly point out and distinctly claim the subject matter of the invention[4].

Subject Matter Eligibility Under 35 U.S.C. § 101

The 2024 Guidance Update by the USPTO highlights the importance of the two-pronged framework for subject matter eligibility, particularly for AI inventions. Under this framework, claims must be directed to a specific, concrete technological advancement or solution to a technical problem to overcome section 101 rejections[3].

Analysis of Patent 10,272,142 Claims

To critically analyze the claims of Patent 10,272,142, one must examine whether they meet the criteria outlined above.

Clarity and Specificity

  • Do the claims clearly and distinctly define the invention?
  • Are the claims broad enough to prevent design-around but narrow enough to avoid prior art?

Subject Matter Eligibility

  • Do the claims pass the subject matter eligibility test under 35 U.S.C. § 101?
  • Are the claims directed to a specific technological advancement or solution to a technical problem?

Trends in Patent Applications and Claims

The number of patent applications and claims has been increasing significantly over the years. This trend is driven by technological innovation and facilitated by advancements in technology such as word processing and remote electronic database searching[2].

Impact of Increasing Claims

  • The rise in the number of claims per patent application can complicate the review process.
  • Automated systems, such as the Patent Matrix software, have been developed to help manage and analyze large numbers of claims efficiently[2].

Challenges in Patent Examination

The USPTO faces several challenges in examining patents, including the need for consistent definitions of patent quality and the impact of incentives on patent quality.

Time Allotted for Examination

  • The USPTO has analyzed the time needed for thorough patent examinations and has increased the time available for certain art units to ensure more thorough reviews[1].

Applicant Readiness

  • The quality of the patent application at the time of submission significantly affects the examination process. The USPTO has developed tools like the Application Readiness Review Form (ARRF) to assess application readiness[1].

Equity and Diversity in Patenting

Recent trends highlight disparities in patenting activity, including geographic, socioeconomic, racial, and gender-based disparities. Initiatives such as the CHIPS and Science Act aim to address these disparities by strengthening regional innovative capacity[5].

Practical Tips for Crafting Effective Arguments

When facing section 101 rejections, it is crucial to understand how the assigned patent examiner applies the subject matter eligibility analysis. Effective arguments under Prong Two of the two-pronged framework involve demonstrating that the claims are directed to a specific technological advancement or solution to a technical problem[3].

Key Takeaways

  • Clear and Specific Claims: Ensuring that patent claims are clear, specific, and meet statutory requirements is crucial for patent quality.
  • Subject Matter Eligibility: Claims must pass the subject matter eligibility test, particularly for emerging technologies like AI.
  • Trends in Patent Applications: The increasing number of patent applications and claims necessitates efficient review systems.
  • Challenges in Patent Examination: Consistent definitions of patent quality and adequate examination time are essential for maintaining high patent quality.
  • Equity and Diversity: Addressing disparities in patenting activity is vital for a diverse and inclusive innovation ecosystem.

FAQs

Q: What are the key requirements for patent claims under U.S. law? A: Patent claims must particularly point out and distinctly define the metes and bounds of the subject matter that will be protected by the patent grant, and they must meet the statutory requirements for novelty, clarity, and non-obviousness[4].

Q: How does the USPTO ensure patent quality? A: The USPTO has implemented various initiatives, including the Enhanced Patent Quality Initiative, which includes defining patent quality, reassessing examination time, and analyzing the effects of incentives on patent quality[1].

Q: What is the significance of the two-pronged framework in subject matter eligibility analysis? A: The two-pronged framework is crucial for determining whether claims are directed to a specific technological advancement or solution to a technical problem, especially for AI inventions[3].

Q: How are disparities in patenting activity addressed? A: Initiatives such as the CHIPS and Science Act aim to strengthen regional innovative capacity and address geographic, socioeconomic, racial, and gender-based disparities in patenting activity[5].

Q: What tools are available to manage and analyze large numbers of patent claims? A: Automated systems like the Patent Matrix software have been developed to facilitate the review and analysis of large numbers of patent claims efficiently[2].

Sources

  1. GAO Report: Intellectual Property: Patent Office Should Define Quality, Reassess Time Allotted for Examination, and Analyze Incentives.
  2. Google Patents: US20110138338A1 - Patent Claims Analysis System and Method.
  3. Baker Botts: The Importance of Prong Two of Step 2A for AI Inventions.
  4. USPTO: Drafting a Provisional Application.
  5. CRS Report: Equity in Innovation: Trends in U.S. Patenting and Inventor Diversity.

More… ↓

⤷  Try for Free

Details for Patent 10,272,142

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 November 26, 1997 10,272,142 2034-11-12
Alexion Pharmaceuticals, Inc. SOLIRIS eculizumab Injection 125166 March 16, 2007 10,272,142 2034-11-12
Genentech, Inc. RITUXAN HYCELA rituximab and hyaluronidase human Injection 761064 June 22, 2017 10,272,142 2034-11-12
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.